Clinical Trial Update: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of JNJ-73763989 and JNJ-56136379 with a nucleos(t)ide analog versus a nucleos(t)ide analog alone in e antigen negative,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-56136379
• JNJ-73763989
• Nucleos(t)ide analog

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2024-07-31